Dear Contractor
Correspondence has been issued by SPPG 3rd July 2024 regarding the recent rise in coronavirus infection and which patients who should be testing.

SUMMARY

  • Due to a possible surge in COVID-19, the PHA have produced a poster for pharmacies to display which provides information to patients on who should be testing for COVID-19 infection and are therefore eligible for free lateral flow tests.
  • The poster contains a QR code which will direct patients to the relevant NI Direct webpage for further information.

ACTION

  • Please review the correspondence issued by SPPG 3rd July 2024 regarding information for patients on the eligibility of free lateral flow tests.
  • SPPG will be sending out posters to community pharmacy to display, however, pharmacies are asked in the meantime to print out the poster or use the jpg to display the poster digitally if possible and preferred.

If you have any queries in relation to this email, please contact your local Primary Care Office.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
Dear Contractor
SPPG have issued an important update on 2nd July 2024 regarding the Spring COVID-19 CPVS programme.

SUMMARY

  • The PHA immunisation team would like to pass on their thanks to community pharmacy teams for their hard work throughout the Spring Booster Campaign.
  • An evaluation exercise will be carried out in relation to the campaign, and further information will be shared once available.
  • The COVID-19 Spring booster campaign ended on 30th June 2024 therefore:
    • The PGD is no longer valid and no further vaccinations should be administered.
    • All unused stock of Spikevax® XBB.1.5 COVID-19 vaccines should be disposed of in line with current guidance.
    • The additional Care Home payment should be claimed for by completion of the online declaration by Friday 5th July.

ACTION

  • Contractors are asked to read the correspondence issued by SPPG 2nd July 2024 regarding the Spring COVID-19 vaccination programme and share with all relevant team members.
  • The PGD for the COVID-19 Spring booster is no longer valid and therefore no further vaccinations should be administered.
  • Any residual Spikevax® XBB.1.5 COVID-19 stock should now be disposed of in waste bins in line with current guidance.
  • The online declaration for completion of Spring COVID-19 vaccinations in Care Homes should be completed by Friday 5th July to receive the additional payment.

If you have any queries relating to this correspondence please contact Gráinne McMahon (Grainne.McMahon4@hscni.net) or Greg Miller  (Greg.Miller@hscni.net).

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
Dear Colleague
The final update of concessionary prices were granted today for June 2024:
DrugPack SizeConcessionary Price
Amantadine 100mg capsules56£13.21
Codeine 15mg tablets28£0.90
Codeine 15mg tablets100£3.21
Codeine 30mg tablets28£1.22
Codeine 30mg tablets100£4.37
Lisinopril 20mg / Hydrochlorothiazide 12.5mg tablets28£10.70
Moxonidine 200microgram tablets28£5.73
Naproxen 250mg gastro-resistant tablets56£2.33
Naproxen 500mg gastro-resistant tablets56£6.03
Ondansetron 4mg tablets10£5.90
Oxycodone 10mg/1ml solution for injection ampoules5£7.35
Oxycodone 5mg/5ml oral solution sugar free250£9.18
Paracetamol 500mg tablets32£0.73
Paracetamol 500mg tablets100£2.28
Sodium valproate 200mg/5ml oral solution sugar free300£8.63
Sotalol 80mg tablets28£1.09
Telmisartan 80mg tablets28£2.45

Concessionary prices will be paid against the usual code, no additional endorsements are needed.

Please continue to notify CPNI of any pricing issues you are experiencing via our Medicine Shortage Reporter.

Concessionary prices are also published on the CPNI website.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive
This update contains important information for community pharmacy teams.

CPNI ALERTS

DOH(NI) ALERTS

BSO ALERTS

Independent Pharmacy Magazine 2024 Awards

Reminder – entries & nominations for this year’s Independent Pharmacy Awards are open for another few weeks until 15th July 2024.  There are 6 categories and the link to enter is here: Enter IPA 24

PHA Training Needs Assessment (Alcohol and Drugs)

This survey is part of a wider assessment of the training needs of those who come into contact with individuals who experience problems due to (own or others) substance use.  The survey is being conducted by Social Market Research (SMR) on behalf of the Public Health Agency.

PHA wishes to ensure that the training needs of professionals and other staff who come into contact with those using substances, or their family members, continue to be met. This survey will help to support this objective and provides those working in the sector with an opportunity to say what is working well, as well as an opportunity to identify gaps in training provision, particularly as needs are changing.

Lunch and Learn; Time to Take Your Medicine

The following invitation has been shared with CPNI for onwards circulation to our members to bring this lunchtime seminar to your attention as it may be of interest:

30th July 2024, 1pm-2pm

A discussion with Vicki Swanton (Partner, DWF Healthcare) and Pharmacist Richard Brown on the role of the pharmacist, their interactions with clinicians and patients, and the pit falls that can lead to claims.

Questions may be submitted in advance via Rebecca.Walton@dwf.law

RSVP

Pharmacy team(s) can keep updated via CPNI’s Contractor Calendar and Contractor Emails.
Or report medicine shortages, pricing and staffing issues via CPNI’s Medicine Shortage Reporter and Situation Reporter.
Please bring this to the attention of your pharmacy team(s).

Kind regards

SENT ON BEHALF OF
Gerard Greene
Chief Executive
Dear Colleague
The second update of concessionary prices were granted today for June 2024:
DrugPack SizeConcessionary Price
Benzydamine 0.15% mouthwash sugar free300£4.74
Brimonidine 0.2% eye drops5£2.98
Carbamazepine 100mg/5ml oral suspension sugar free300£13.46
Chlorphenamine 2mg/5ml oral solution sugar free150£2.61
Co-amoxiclav 250mg/62mg/5ml oral suspension sugar free100£1.99
Erythromycin 250mg gastro-resistant tablets28£23.50
Erythromycin 40mg/ml / Zinc acetate 12mg/ml lotion30£16.78
Erythromycin 40mg/ml / Zinc acetate 12mg/ml lotion90£40.04
Fluticasone furoate 27.5micrograms/dose nasal spray120£12.37
Fusidic acid 2% cream15£1.98
Fusidic acid 2% cream30£3.70
Lamotrigine 5mg dispersible tablets sugar free28£9.47
Lercanidipine 10mg tablets28£2.50
Lercanidipine 20mg tablets28£5.66
Levetiracetam 500mg tablets60£3.40
Losartan 12.5mg tablets28£3.52
Nefopam 30mg tablets90£4.13
Olanzapine 2.5mg tablets28£2.59
Olanzapine 7.5mg tablets28£1.89
Olopatadine 1mg/ml eye drops5£3.97
Oxytetracycline 250mg tablets28£2.18
Pregabalin 225mg capsules56£2.11
Pregabalin 25mg capsules56£1.51
Propantheline bromide 15mg tablets112£107.49
Quinagolide 50microgram tablets and Quinagolide 25microgram tablets6£40.40
Risperidone 2mg tablets60£1.92
Ropinirole 2mg tablets28£29.56
Sertraline 100mg tablets28£1.78
Sertraline 50mg tablets28£1.02
Tacrolimus 0.1% ointment30£22.52
Tamoxifen 20mg tablets30£5.94
Venlafaxine 75mg modified-release tablets30£2.73

Concessionary prices will be paid against the usual code, no additional endorsements are needed.

Please continue to notify CPNI of any pricing issues you are experiencing via our Medicine Shortage Reporter.

Concessionary prices are also published on the CPNI website.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive

Dear Contractor

Further to CPNI CU#240610A: Proposed Rota Changes CPNI are aware that a number of contractors raised concerns with their local SPPG office on the proposed changes to rota in their area.

Local offices have now issued letters to those contractors affected by the proposed rota changes. For those areas where there was no objection the changes are proceeding as proposed. In areas where issues were raised, the current rota arrangements will be continuing until further notice. Local offices have communicated the rota arrangements over the coming weeks with the community pharmacies involved.

CPNI is disappointed by the lack of notice contractors were given regarding the proposed rota changes, the timelines for providing feedback, the uncertainty there has been around rota provision moving into the summer period and the lack of additional funding to support this service at this time.

SPPG has issued letters to community pharmacies that stated: “CPNI were content with the approach to the review, and agreed to consult with the affected pharmacies as required.  At that time, CPNI did not raise any concerns from contractors potentially affected by the proposed changes.”

CPNI is disappointed at this misrepresentation. CPNI advised SPPG that it was for local offices to consult with the pharmacies involved in rota in their area to determine how rota should be taken forward in each area. CPNI has continually raised concerns, including specific contractor concerns, on the arrangements for rota provision moving forward. CPNI had also asked to discuss the rota arrangements further once local offices had collated the feedback. CPNI did not have sight of the letters that were issued to contractors in advance and have asked SPPG to correct the paragraph quoted above.

CPNI will continue to work with SPPG to try and arrive at workable rota arrangements moving forward that are fairly planned, communicated and remunerated.

Please do not hesitate to contact CPNI office should you have any questions.

Kind regards

SENT ON BEHALF OF
GERARD GREENE
Chief Executive